Ibritumomab tiuxetan (Zevalin)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:31, 13 May 2012 by Dryang (talk | contribs) (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

General information

Class/mechanism: Anti-CD20 antibody chelated by tiuxetan to a radioactive agent (Y-90, yttrium-90; or In-111, indium-111). Y-90 emits beta radiation, which causes cellular damage via free radicals. This results in damage to cells which express the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35).[1][2]
Route: IV
Extravasation: potential vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Ibritumomab tiuxetan (Zevalin) package insert
  2. ↑ Ibritumomab tiuxetan (Zevalin) package insert (locally hosted backup)
  3. ↑ Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)
  4. ↑ Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Ibritumomab_tiuxetan_(Zevalin)&oldid=1410"